Magdalena Flejsierowicz, MD
Hematology & Oncology · Milwaukee, WINPI 1144246737
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,640 of the $4,292 with a category attached, or 61.5%. Verastem, Inc. accounts for 64.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $2,956 and has fallen 94.5% since, to $161 in 2023.
Across 13 payments — averaging $330.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Verastem, Inc.$3K
- Puma Biotechnology, Inc.$1K
- Johnson & Johnson$197
- Bristol Myers Squibb$119
- Astellas Pharma US Inc$119
- E.r. Squibb & Sons, L.L.C.$38
- plus $55 from 3 others
Across 1 payment — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10K
What the payments were for
- Consulting fees$1,00023%
- Speaking & faculty fees$2,64062%
- Food & beverage$59914%
- Education$531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Verastem, Inc. | 2 | $2,764 |
| Puma Biotechnology, Inc. | 1 | $1,000 |
| Johnson & Johnson | 3 | $197 |
| Bristol Myers Squibb | 1 | $119 |
| Astellas Pharma US Inc | 1 | $119 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Merck | 1 | $25 |
| AstraZeneca | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,292 in reported general payments places this provider in the 70th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $32,445 |
| Abiraterone Acetate | 36 | $20,532 |
| Anastrozole | 239 | $3,838 |
| Exemestane | 19 | $1,661 |
| Ondansetron Hcl | 13 | $954 |
| Tamoxifen Citrate | 24 | $638 |
| Hydroxyurea | 28 | $570 |
| Letrozole | 21 | $513 |
| Dexamethasone | 19 | $484 |
| Pantoprazole Sodium | 13 | $411 |
| Prochlorperazine Maleate | 19 | $271 |
| Warfarin Sodium | 19 | $232 |
| Prednisone | 42 | $185 |
| Potassium Chloride | 12 | $144 |
| Gabapentin | 11 | $130 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Milwaukee
- Parameswaran HariMilwaukee$1.3M
- Sayed Mehdi HamadaniMilwaukee$546K
- Binod DhakalMilwaukee$535K
- Deepak KilariMilwaukee$359K
- Ehab AtallahMilwaukee$344K
- Nirav ShahMilwaukee$207K
- Razelle KurzrockMilwaukee$199K
- Syed AbutalibMilwaukee$154K
- Patrick FoyMilwaukee$132K
- Guru Subramanian Guru MurthyMilwaukee$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.